These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery. Wang SH; Thompson AL; Hickey AJ; Staats HF Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816 [TBL] [Abstract][Full Text] [Related]
47. Immunomodulators and delivery systems for vaccination by mucosal routes. Ryan EJ; Daly LM; Mills KH Trends Biotechnol; 2001 Aug; 19(8):293-304. PubMed ID: 11451471 [TBL] [Abstract][Full Text] [Related]
48. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant. Hafner AM; Corthésy B; Merkle HP Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781 [TBL] [Abstract][Full Text] [Related]
49. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926 [TBL] [Abstract][Full Text] [Related]
50. Phospholipid bilayer-coated aluminum nanoparticles as an effective vaccine adjuvant-delivery system. Wang T; Zhen Y; Ma X; Wei B; Wang N ACS Appl Mater Interfaces; 2015 Apr; 7(12):6391-6. PubMed ID: 25780860 [TBL] [Abstract][Full Text] [Related]
51. Advances and challenges in mucosal adjuvant technology. Newsted D; Fallahi F; Golshani A; Azizi A Vaccine; 2015 May; 33(21):2399-405. PubMed ID: 25865473 [TBL] [Abstract][Full Text] [Related]
52. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762 [TBL] [Abstract][Full Text] [Related]
53. Delivery strategies to enhance oral vaccination against enteric infections. Davitt CJ; Lavelle EC Adv Drug Deliv Rev; 2015 Aug; 91():52-69. PubMed ID: 25817337 [TBL] [Abstract][Full Text] [Related]
54. Mass vaccination: solutions in the skin. Glenn GM; Kenney RT Curr Top Microbiol Immunol; 2006; 304():247-68. PubMed ID: 16989274 [TBL] [Abstract][Full Text] [Related]
55. Immunity in response to particulate antigen-delivery systems. Storni T; Kündig TM; Senti G; Johansen P Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945 [TBL] [Abstract][Full Text] [Related]
56. Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies. Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V Int J Pharm; 2013 Jan; 441(1-2):636-42. PubMed ID: 23117021 [TBL] [Abstract][Full Text] [Related]
57. Liposomal vaccine delivery systems. Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904 [TBL] [Abstract][Full Text] [Related]